Activity of α2,6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy

Scandinavian Journal of Immunology

Volumn 69, Issue 2, 2009, Pages 174-180

  Ding, J X ^a   Xu, L X ^a   Zhu, L ^a   Lv, J C ^a   Zhao, M H ^a   Zhang, H ^a   Wang, H Y ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2,6 SIALIC ACID; ALPHA2,6 SIALYLTRANSFERASE; CD19 ANTIBODY; IMMUNOGLOBULIN A1; MESSENGER RNA; SIALIC ACID; SIALYLTRANSFERASE; UNCLASSIFIED DRUG; BETA D GALACTOSIDE ALPHA 2 6 SIALYLTRANSFERASE; BETA-D-GALACTOSIDE ALPHA 2-6-SIALYLTRANSFERASE; GALACTOSYL 1 3 N ACETYLGALACTOSAMINYL SPECIFIC 2,6 SIALYLTRANSFERASE; GALACTOSYL-1-3-N-ACETYLGALACTOSAMINYL-SPECIFIC 2,6-SIALYLTRANSFERASE; IMMUNOGLOBULIN A;

ADULT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A NEPHROPATHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIALYLATION; ST6GALNAC2 GENE; BLOOD; ENZYMOLOGY; GENETICS; GLYCOSYLATION; METABOLISM;

ADULT; B-LYMPHOCYTES; FEMALE; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN A; MALE; RNA, MESSENGER; SIALYLTRANSFERASES;

EID: 58849123408     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02204.x     Document Type: Article

References (35)

1. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988 12 : 340 7.
2. Berger J, Hinglais N. [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) 1968 74 : 694 5.
3. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 2004 65 : 1544 7.
4. Shimozato S, Hiki Y, Odani H, Takahashi K, Yamamoto K, Sugiyama S. Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Nephrol Dial Transplant 2008 23 : 1931 9.
5. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995 100 : 470 4.
6. Baharaki D, Dueymes M, Perrichot R et al. Aberrant glycosylation of IgA from patients with IgA nephropathy. Glycoconj J 1996 13 : 505 11.
7. Moldoveanu Z, Wyatt RJ, Lee JY et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007 71 : 1148 54.
8. Linossier MT, Palle S, Berthoux F. Different glycosylation profile of serum IgA1 in IgA nephropathy according to the glomerular basement membrane thickness: normal versus thin. Am J Kidney Dis 2003 41 : 558 64.
9. Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997 52 : 509 16.
10. Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 1999 10 : 1763 71.
11. Hiki Y, Tanaka A, Kokubo T et al. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Am Soc Nephrol 1998 9 : 577 82.
12. Odani H, Hiki Y, Takahashi M et al. Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry. Biochem Biophys Res Commun 2000 271 : 268 74.
13. Renfrow MB, Cooper HJ, Tomana M et al. Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem 2005 280 : 19136 45.
14. Leung JC, Tang SC, Chan DT, Lui SL, Lai KN. Increased sialylation of polymeric lambda-IgA1 in patients with IgA nephropathy. J Clin Lab Anal 2002 16 : 11 9.
15. Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001 60 : 969 73.
16. Hiki Y, Odani H, Takahashi M et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001 59 : 1077 85.
17. Xu LX, Zhao MH. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int 2005 68 : 167 72.
18. Ding JX, Xu LX, Lv JC, Zhao MH, Zhang H, Wang HY. Aberrant sialylation of serum IgA1 was associated with prognosis of patients with IgA nephropathy. Clin Immunol 2007 125 : 268 74.
19. Li GS, Zhu L, Zhang H et al. Variants of the ST6GALNAC2 promoter influence transcriptional activity and contribute to genetic susceptibility to IgA nephropathy. Hum Mutat 2007 28 : 950 57.
20. Raska M, Moldoveanu Z, Andrasi J et al. Identification of a candidate gene for CMP-NeuAc:GalNac-IgA1 α 2, 6-sialyltransferase in an IgA1-producing cell line. 10th International Symposium on IgA. Nephropathy 2004 40 : 26 7 (abstr).
21. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997 29 : 829 42.
22. Westerhuis R, Van Zandbergen G, Verhagen NA, Klar-Mohamad N, Daha MR, van Kooten C. Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). J Am Soc Nephrol 1999 10 : 770 8.
23. Yan Y, Xu LX, Zhang JJ, Zhang Y, Zhao MH. Self-aggregated deglycosylated IgA1 with or without IgG were associated with the development of IgA nephropathy. Clin Exp Immunol 2006 144 : 17 24.
24. Basset C, Durand V, Jamin C et al. Increased N-linked glycosylation leading to oversialylation of monomeric immunoglobulin A1 from patients with Sjogren's syndrome. Scand J Immunol 2000 51 : 300 6.
25. Suzuki H, Moldoveanu Z, Hall S et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008 118 : 629 39.
26. Eijgenraam JW, van Kooten C. IgA1 glycosylation in IgA nephropathy: as sweet as it can be. Kidney Int 2008 73 : 1106 8.
27. Buck KS, Smith AC, Molyneux K, El-Barbary H, Feehally J, Barratt J. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int 2008 73 : 1128 36.
28. Qin W, Zhou Q, Yang LC et al. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med 2005 258 : 467 77.
29. Buck K, Barratt J, Feehally J, Smith A. Beta-1-3-galactosyltransferase activity in IgA nephropathy. J Am Soc Nephrol 2003 14 : 632 (abstr).
30. Allen AC, Topham PS, Harper SJ, Feehally J. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant 1997 12 : 701 6.
31. Smith AC, de Wolff JF, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 2006 17 : 1192 9.
32. Kokubo T, Hiki Y, Iwase H et al. Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy. J Am Soc Nephrol 1997 8 : 915 9.
33. Hashim OH, Shuib AS, Chua CT. The interaction of selective plant lectins with neuraminidase-treated and untreated IgA1 from the sera of IgA nephropathy patients. Immunol Invest 2001 30 : 21 31.
34. Xu LX, Yan Y, Zhang JJ, Zhang Y, Zhao MH. The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy. Clin Exp Immunol 2005 142 : 569 75.
35. Gastaldi D, Paradisi L, Baiocchi C et al. Mass spectrometry analysis of IgA1 hinge region in patients with IgA nephropathy. J Nephrol 2007 20 : 689 95.